Literature DB >> 6651877

Phosphorolysis of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and other 5-substituted-2'-deoxyuridines by purified human thymidine phosphorylase and intact blood platelets.

C Desgranges, G Razaka, M Rabaud, H Bricaud, J Balzarini, E De Clercq.   

Abstract

Various 5-substituted-2'-deoxyuridines (dUrd), including 5-ethyl,5-propyl-, 5-trifluoromethyl-, 5-hydroxymethyl-, 5-formyl-, 5-vinyl-, (E)-5-(2-chlorovinyl)-, (E)-5-(2-bromovinyl)-, 5-fluoro-, 5-chloro-, 5-bromo-, 5-iodo-, 5-cyano-, 5-thiocyano-, 5-nitro- and 5-amino-dUrd, were shown to be effective substrates for the thymidine (dThd) phosphorylase isolated from human blood platelets. Some of dUrd analogs, i.e. the highly potent and selective antiherpes agent (E)-5-(2-bromovinyl)-dUrd, were degraded more rapidly than the natural substrates, dUrd and dThd. All dUrd analogs were also readily catabolised by intact human blood platelets. The potent inhibitors of thymidine phosphorylase, 6-amino-thymine and 6-amino-5-bromo-uracil, strongly inhibited the phosphorolysis of (E)-5-(2-bromovinyl)-dUrd by both purified enzyme and intact platelets.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6651877     DOI: 10.1016/0006-2952(83)90307-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  16 in total

1.  Anti-(herpes simplex virus) activity of 4'-thio-2'-deoxyuridines: a biochemical investigation for viral and cellular target enzymes.

Authors:  A Verri; F Focher; R J Duncombe; I Basnak; R T Walker; P L Coe; E de Clercq; G Andrei; R Snoeck; J Balzarini; S Spadari
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  Human platelet-derived endothelial cell growth factor is homologous to Escherichia coli thymidine phosphorylase.

Authors:  G J Barton; C P Ponting; G Spraggon; C Finnis; D Sleep
Journal:  Protein Sci       Date:  1992-05       Impact factor: 6.725

3.  Structural basis for non-competitive product inhibition in human thymidine phosphorylase: implications for drug design.

Authors:  Kamel El Omari; Annelies Bronckaers; Sandra Liekens; Maria-Jésus Pérez-Pérez; Jan Balzarini; David K Stammers
Journal:  Biochem J       Date:  2006-10-15       Impact factor: 3.857

4.  Selective in vitro and in vivo activities of 5-(2-haloalkyl)pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus.

Authors:  E De Clercq; B Rosenwirth
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

5.  Relaxed enantioselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of L-nucleoside analogues.

Authors:  A Verri; G Priori; S Spadari; L Tondelli; F Focher
Journal:  Biochem J       Date:  1997-11-15       Impact factor: 3.857

Review 6.  Structure-activity relationships and conformational features of antiherpetic pyrimidine and purine nucleoside analogues. A review.

Authors:  T Kulikowski
Journal:  Pharm World Sci       Date:  1994-04-15

7.  Regeneration of the antiviral drug (E)-5-(2-bromovinyl)-2'-deoxyuridine in vivo.

Authors:  C Desgranges; G Razaka; F Drouillet; H Bricaud; P Herdewijn; E De Clercq
Journal:  Nucleic Acids Res       Date:  1984-02-24       Impact factor: 16.971

Review 8.  Antiherpes drugs: promises and pitfalls.

Authors:  E de Clercq
Journal:  Eur J Clin Microbiol       Date:  1984-04       Impact factor: 3.267

9.  Metabolism of anti-herpes agent 5-(2-chloroethyl)-2'-deoxyuridine in mice and rats.

Authors:  I Szinai; Z Veres; K Ganzler; J Hegedus-Vajda; E De Clercq
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Apr-Jun       Impact factor: 2.441

10.  Pharmacokinetics and metabolism of E-5-(2-[131I]iodovinyl)-2'-deoxyuridine in dogs.

Authors:  J Samuel; M J Gill; T Iwashina; D R Tovell; D L Tyrrell; E E Knaus; L I Wiebe
Journal:  Antimicrob Agents Chemother       Date:  1986-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.